Drug of Choice for Pneumonia in a 12-Year-Old
For a previously healthy 12-year-old with community-acquired pneumonia, oral amoxicillin at 90 mg/kg/day (divided into 2 doses) is the drug of choice for outpatient treatment, with the addition of a macrolide (azithromycin) if atypical pathogens like Mycoplasma pneumoniae are suspected based on clinical presentation.
Treatment Algorithm by Severity
Outpatient (Mild-to-Moderate CAP)
Primary therapy:
- Amoxicillin 90 mg/kg/day in 2 divided doses (or 45 mg/kg/day in 3 doses) 1
- This targets Streptococcus pneumoniae, the most common bacterial pathogen at this age
Add macrolide if atypical pathogens suspected:
- Azithromycin 10 mg/kg on day 1, then 5 mg/kg/day for days 2-5 1
- Consider this addition if the child presents with gradual onset, prominent cough, lack of high fever, or minimal chest findings—features suggesting M. pneumoniae or C. pneumoniae
- At age 12, atypical bacteria become increasingly common causes 1
Alternative for β-lactam allergy:
- Azithromycin alone or clarithromycin (15 mg/kg/day in 2 doses) 1
Hospitalized (Severe CAP)
Parenteral therapy:
- Ampicillin 150-200 mg/kg/day IV every 6 hours OR ceftriaxone 50-100 mg/kg/day IV every 12-24 hours 1
- Add azithromycin IV (10 mg/kg on days 1-2) if M. pneumoniae or C. pneumoniae are significant considerations 1
Step-down to oral therapy once clinically stable, completing treatment with oral amoxicillin ± azithromycin
Duration of Treatment
- 3-5 days minimum for uncomplicated cases that achieve clinical stability 2, 3, 4
- Traditional 7-10 day courses are no longer necessary for most cases
- Continue until the child is afebrile for 24-48 hours and clinically improving
Key Clinical Considerations
When to add macrolide coverage:
- School-age children (5+ years) have higher rates of atypical pathogens 5
- Clinical clues: subacute presentation, prominent cough, lack of toxic appearance, interstitial infiltrates on imaging
- The guideline recommends empiric combination therapy for hospitalized children when atypicals are "significant considerations" 1
When to escalate therapy:
- If no improvement within 48 hours, reassess for complications or resistant organisms
- Consider adding vancomycin or clindamycin if S. aureus (including MRSA) is suspected based on severe illness, empyema, or necrotizing features 1
Common Pitfalls to Avoid
Overuse of broad-spectrum antibiotics: Third-generation cephalosporins are not superior to amoxicillin for typical pneumococcal pneumonia and unnecessarily broaden coverage 1, 6
Ignoring atypical pathogens: At age 12, M. pneumoniae is common and won't respond to β-lactams alone—maintain a low threshold for adding macrolide coverage 1, 5
Prolonged treatment courses: Recent evidence supports shorter durations (3-5 days) for uncomplicated cases 2, 3
Withholding antibiotics based solely on viral testing: Even with positive viral tests, bacterial co-infection is common; treat based on clinical presentation and imaging findings 7
The evidence strongly supports narrow-spectrum β-lactam therapy as first-line treatment, with selective addition of macrolides based on age and clinical presentation 1, 2, 4. This approach balances efficacy against the most common pathogens while minimizing antibiotic resistance and adverse effects on the developing microbiome 2.